50. Dermatomyositis Clinical trials / Disease details

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03857854 (ClinicalTrials.gov)	June 5, 2018	26/2/2019	Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)	A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD)	Dermatomyositis Interstitial Lung Disease (Dm-ILD)	Drug: Pirfenidone;Drug: Placebos	Beijing Continent Pharmaceutical Co, Ltd.	NULL	Recruiting	18 Years	65 Years	All	152	Phase 3	China
2	NCT02821689 (ClinicalTrials.gov)	July 2016	21/6/2016	Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis	Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis	Dermatopolymyositis;Interstitial Lung Disease	Drug: Pirfenidone	RenJi Hospital	NULL	Not yet recruiting	16 Years	N/A	Both	57	Phase 4	China
3	ChiCTR-IPR-16007958	2014-06-01	2016-02-21	An observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositis	An observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositis	clinically amyopathic dermatomyositis	Rsearch group: glucocorticoids+immunosuppressant+pirfenidone;Control group: glucocorticoids+immunosuppressant;	Renji Hospital, Shanghai Jiaotong University School of Medicine	NULL	Completed			Both	Rsearch group:30;Control group:30;		China